TY - JOUR
T1 - A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency in children in rural Alaska
AU - Gessner, Bradford D.
AU - Baggett, Henry C.
AU - Muth, Pam T.
AU - Dunaway, Eitel
AU - Gold, Benjamin D.
AU - Feng, Ziding
AU - Parkinson, Alan J.
N1 - Funding Information:
Potential conflicts of interest: B. D. Gessner has received funding support from Sanofi-Pasteur. B. D. Gold has selVed as a consultant for TAP Pharmaceuticals, AstraZeneca, and Romark Laboratories. The remaining authors report no conflicts of interest. TAP Pharmaceuticals provided lansoprazole and was provided with a prepublication version of the final results but had no role in the design and conduct of the study; the collection, management, analysis, or interpretation of the data; or preparation or approval of the manuscript. Financial support: US federal grant (directed source 02079/grant 1D1ARH00135-01 0 to the Alaska Department of Health and Social SelVices) .; Present affiliation: Division of Quarantine, US Centers for Disease Control and Prevention, Atlanta, Georgia.
PY - 2006/2/15
Y1 - 2006/2/15
N2 - Background. Helicobacter pylori infection and iron deficiency are prevalent in disadvantaged populations world-wide. Previous small or uncontrolled studies have reported that successful treatment of H. pylori infection may resolve iron deficiency or anemia. Methods. We screened 68% of children 7-11 years old living in 10 western Alaska villages. The 219 children with iron deficiency (serum ferritin level, <22.5 pmol/L [<10 pig/L]) and H. pylori infection (diagnosed on the basis of "C-labeled urea breath tests) were enrolled in a household-randomized, unblinded trial. All children received iron supplementation for 6 weeks; children in the intervention group also received a 2-week course of treatment for H. pylori infection plus another 2-week course of treatment if the infection had not resolved at 2 months after treatment initiation. Results. At 2 months after treatment initiation, 32% of children in the intervention group and 39% of children in the control group had iron deficiency. At 14 months after treatment initiation, 65% of children in the intervention group and 72% of children in the control group had iron deficiency (adjusted relative risk [ARR], 0.90 [95% confidence interval {CI}, 0.74-1.1]); in addition, 22% of children in the intervention group and 14% of children in the control group had anemia (ARR, 1.6 [95% CI, 0.86-2.9] ). Results were similar when children were compared by H. pylori infection status. Conclusions. In a high-prevalence population, treatment and resolution of H. pylori infection did not improve isolated iron deficiency or mild anemia up to 14 months after treatment initiation.
AB - Background. Helicobacter pylori infection and iron deficiency are prevalent in disadvantaged populations world-wide. Previous small or uncontrolled studies have reported that successful treatment of H. pylori infection may resolve iron deficiency or anemia. Methods. We screened 68% of children 7-11 years old living in 10 western Alaska villages. The 219 children with iron deficiency (serum ferritin level, <22.5 pmol/L [<10 pig/L]) and H. pylori infection (diagnosed on the basis of "C-labeled urea breath tests) were enrolled in a household-randomized, unblinded trial. All children received iron supplementation for 6 weeks; children in the intervention group also received a 2-week course of treatment for H. pylori infection plus another 2-week course of treatment if the infection had not resolved at 2 months after treatment initiation. Results. At 2 months after treatment initiation, 32% of children in the intervention group and 39% of children in the control group had iron deficiency. At 14 months after treatment initiation, 65% of children in the intervention group and 72% of children in the control group had iron deficiency (adjusted relative risk [ARR], 0.90 [95% confidence interval {CI}, 0.74-1.1]); in addition, 22% of children in the intervention group and 14% of children in the control group had anemia (ARR, 1.6 [95% CI, 0.86-2.9] ). Results were similar when children were compared by H. pylori infection status. Conclusions. In a high-prevalence population, treatment and resolution of H. pylori infection did not improve isolated iron deficiency or mild anemia up to 14 months after treatment initiation.
UR - http://www.scopus.com/inward/record.url?scp=32044445537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32044445537&partnerID=8YFLogxK
U2 - 10.1086/499604
DO - 10.1086/499604
M3 - Article
C2 - 16425133
AN - SCOPUS:32044445537
SN - 0022-1899
VL - 193
SP - 537
EP - 546
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -